What is Enliven Therapeutics Inc. (ELVN) stock price today?

Enliven Therapeutics Inc. (ELVN) currently trades at $41.23 per share. The stock has a market capitalization of $2.58B and a P/E ratio of —x.

Is ELVN stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Enliven Therapeutics Inc. has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 10.54.

Is Enliven Therapeutics Inc. financially healthy?

Enliven Therapeutics Inc.'s Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 10.54 places it in the safe zone.

ELVN

Enliven Therapeutics Inc.

NASDAQ: ELVN · HEALTHCARE · BIOTECHNOLOGY

$41.23

-2.76% today

Updated 2026-04-30

Market cap

$2.58B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.83

Dividend yield

—

52W range

$15 – $49

Volume

1.2M

Market cap

$2.58B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.83

Dividend yield

—

52W range

$15 – $49

Volume

1.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.3

Quality

B+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

10.5

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$51.29

+24.40%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 10.54 — safe zone

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-15.84M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-37.66M	$-71.58M	$-89.02M	$-103.69M	$-29.67M
EPS	—	—	—	—	$-1.83
Free cash flow	$-32.69M	$-61.42M	$-73.24M	$-70.46M	$-15.84M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ELVN	$2.58B	25	4.3	3.0	5.0	7.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Enliven Therapeutics Inc. trades at $41.23. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 10.54, it sits in the safe zone.

Frequently asked questions

What is Enliven Therapeutics Inc.'s stock price?

Enliven Therapeutics Inc. (ELVN) trades at $41.23.

Is Enliven Therapeutics Inc. overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell).

What is the price target of Enliven Therapeutics Inc. (ELVN)?

The analyst target price is $51.29, representing +24.4% upside from the current price of $41.23.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

10.54 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-27.00%

Beta0.49

50D MA$35.68

200D MA$24.69

Shares out0.06B

Float0.03B

Short ratio—

Avg volume1.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ELVN vs LLY →ELVN vs JNJ →ELVN vs ABBV →Stock screener →